{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T13:34:15Z","timestamp":1789392855519,"version":"build-2803163510"},"reference-count":24,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","nmd-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuromuscular Disorders"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1016\/j.nmd.2022.06.001","type":"journal-article","created":{"date-parts":[[2022,6,2]],"date-time":"2022-06-02T21:28:39Z","timestamp":1654205319000},"page":"682-686","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Refractory Morvan syndrome responsive to rituximab: a case report and review of the literature"],"prefix":"10.1016","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7066-1811","authenticated-orcid":false,"given":"Omar","family":"Nawfal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad","family":"Agha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Achraf","family":"Makki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9047-1185","authenticated-orcid":false,"given":"Ahmad","family":"Beydoun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.nmd.2022.06.001_bib0001","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1016\/S0140-6736(17)30557-3","article-title":"Morvan just a syndrome\u2026!","volume":"389","author":"Somerville","year":"2017","journal-title":"Lancet North Am Ed"},{"key":"10.1016\/j.nmd.2022.06.001_bib0002","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1002\/ana.23577","article-title":"Morvan syndrome: clinical and serological observations in 29 cases","volume":"72","author":"Irani","year":"2012","journal-title":"Ann Neurol"},{"key":"10.1016\/j.nmd.2022.06.001_bib0003","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1212\/WNL.0000000000002917","article-title":"The clinical spectrum of Caspr2 antibody\u2013associated disease","volume":"87","author":"van Sonderen","year":"2016","journal-title":"Neurology"},{"key":"10.1016\/j.nmd.2022.06.001_bib0004","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1136\/jnnp-2017-315720","article-title":"LGI1, CASPR2 and related antibodies: a molecular evolution of the phenotypes","volume":"89","author":"Binks","year":"2018","journal-title":"Journal of Neurology, Neurosurgery & Psychiatry"},{"key":"10.1016\/j.nmd.2022.06.001_bib0005","doi-asserted-by":"crossref","first-page":"e155","DOI":"10.1111\/epi.13436","article-title":"Subclinical temporal EEG seizure pattern in LGI 1-antibody\u2013mediated encephalitis","volume":"57","author":"Steriade","year":"2016","journal-title":"Epilepsia"},{"key":"10.1016\/j.nmd.2022.06.001_bib0006","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.652864","article-title":"Clinical Character of CASPR2 Autoimmune Encephalitis: A Multiple Center Retrospective Study","volume":"12","author":"Qin","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.nmd.2022.06.001_bib0007","doi-asserted-by":"crossref","first-page":"2076","DOI":"10.1212\/WNL.0000000000002037","article-title":"Peripheral small fiber dysfunction and neuropathic pain in patients with Morvan syndrome","volume":"85","author":"Laurencin","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.nmd.2022.06.001_bib0008","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1002\/ana.26189","article-title":"Leucine-Rich Glioma-Inactivated 1 versus Contactin-Associated Protein-like 2 antibody neuropathic pain: clinical and biological comparisons","volume":"90","author":"Ramanathan","year":"2021","journal-title":"Ann Neurol"},{"key":"10.1016\/j.nmd.2022.06.001_bib0009","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1016\/j.neuron.2018.01.033","article-title":"Immune or genetic-mediated disruption of CASPR2 causes pain hypersensitivity due to enhanced primary afferent excitability","volume":"97","author":"Dawes","year":"2018","journal-title":"Neuron"},{"key":"10.1016\/j.nmd.2022.06.001_bib0010","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1007\/s00415-019-09686-2","article-title":"Systematic review of the clinical spectrum of CASPR2 antibody syndrome","volume":"267","author":"Boyko","year":"2020","journal-title":"J Neurol"},{"key":"10.1016\/j.nmd.2022.06.001_bib0011","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1097\/CND.0b013e31822b1977","article-title":"Morvan syndrome: a case report and review of the literature","volume":"13","author":"Abou-Zeid","year":"2012","journal-title":"Journal of clinical neuromuscular disease"},{"key":"10.1016\/j.nmd.2022.06.001_bib0012","doi-asserted-by":"crossref","DOI":"10.1016\/j.jneuroim.2020.577197","article-title":"Mercury-induced autoimmunity: report of two adolescent siblings with Morvan syndrome \u201cplus\u201d and review of the literature","volume":"342","author":"P\u00e9rez","year":"2020","journal-title":"J Neuroimmunol"},{"key":"10.1016\/j.nmd.2022.06.001_bib0013","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1097\/NRL.0000000000000266","article-title":"Morvan Syndrome and Diffuse Large B-Cell Lymphoma in the Central Nervous System","volume":"25","author":"Jiang","year":"2020","journal-title":"Neurologist"},{"key":"10.1016\/j.nmd.2022.06.001_bib0014","article-title":"Morvan's syndrome treated successfully with rituximab and lacosamide","volume":"12","author":"Sveinsson","year":"2019","journal-title":"BMJ Case Reports CP"},{"key":"10.1016\/j.nmd.2022.06.001_bib0015","doi-asserted-by":"crossref","first-page":"e96","DOI":"10.1111\/ene.12164","article-title":"Dramatic improvement after rituximab in a patient with paraneoplastic treatment-refractory Morvan syndrome associated with anti-CASPR2 antibodies","volume":"20","author":"Ong","year":"2013","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.nmd.2022.06.001_bib0016","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1002\/mus.23311","article-title":"Rituximab therapy for morvan syndrome associated with myasthenia gravis","volume":"46","author":"Weiss","year":"2012","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.nmd.2022.06.001_bib0017","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1136\/jnnp.2009.174888","article-title":"Rituximab in the treatment of three coexistent neurological autoimmune diseases: chronic inflammatory demyelinating polyradiculoneuropathy, Morvan syndrome and myasthenia gravis","volume":"82","author":"Sadnicka","year":"2011","journal-title":"Journal of Neurology, Neurosurgery & Psychiatry"},{"key":"10.1016\/j.nmd.2022.06.001_bib0018","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/ncpneuro0526","article-title":"Antibodies to AChR, MuSK and VGKC in a patient with myasthenia gravis and Morvan's syndrome","volume":"3","author":"D\u00edaz-Manera","year":"2007","journal-title":"Nature clinical practice Neurology"},{"key":"10.1016\/j.nmd.2022.06.001_bib0019","doi-asserted-by":"crossref","first-page":"2734","DOI":"10.1093\/brain\/awq213","article-title":"Antibodies to Kv1 potassium channel-complex proteins leucine-rich, glioma inactivated 1 protein and contactin-associated protein-2 in limbic encephalitis, Morvan\u2019s syndrome and acquired neuromyotonia","volume":"133","author":"Irani","year":"2010","journal-title":"Brain"},{"key":"10.1016\/j.nmd.2022.06.001_bib0020","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1136\/jnnp-2016-314758","article-title":"Intracellular and non-neuronal targets of voltage-gated potassium channel complex antibodies","volume":"88","author":"Lang","year":"2017","journal-title":"Journal of Neurology, Neurosurgery & Psychiatry"},{"key":"10.1016\/j.nmd.2022.06.001_bib0021","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000001088","article-title":"Rituximab Treatment and Long-term Outcome of Patients With Autoimmune Encephalitis: Real-world Evidence From the GENERATE Registry","volume":"8","author":"Thaler","year":"2021","journal-title":"Neurology-Neuroimmunology Neuroinflammation"},{"key":"10.1016\/j.nmd.2022.06.001_bib0022","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.jocn.2017.02.063","article-title":"Isaacs syndrome with CASPR2 antibody: a series of three cases","volume":"41","author":"Song","year":"2017","journal-title":"J Clin Neurosci"},{"key":"10.1016\/j.nmd.2022.06.001_bib0023","article-title":"Autoimmune encephalitis: proposed recommendations for symptomatic and long-term management","author":"Abboud","year":"2021","journal-title":"Journal of Neurology, Neurosurgery & Psychiatry"},{"key":"10.1016\/j.nmd.2022.06.001_bib0024","doi-asserted-by":"crossref","first-page":"203","DOI":"10.2147\/NDT.S292343","article-title":"Clinical features and long-term outcomes of anti-leucine-rich glioma-inactivated 1 encephalitis: a multi-center study","volume":"17","author":"Qiao","year":"2021","journal-title":"Neuropsychiatric Disease and Treatment"}],"container-title":["Neuromuscular Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960896622001663?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960896622001663?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T08:13:11Z","timestamp":1760775191000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960896622001663"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8]]},"references-count":24,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2022,8]]}},"alternative-id":["S0960896622001663"],"URL":"https:\/\/doi.org\/10.1016\/j.nmd.2022.06.001","relation":{},"ISSN":["0960-8966"],"issn-type":[{"value":"0960-8966","type":"print"}],"subject":[],"published":{"date-parts":[[2022,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Refractory Morvan syndrome responsive to rituximab: a case report and review of the literature","name":"articletitle","label":"Article Title"},{"value":"Neuromuscular Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nmd.2022.06.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}